. In addition, some analogs specifically block the membranemediated effects of 1␣,25-(OH) 2 D 3 (15). Similarly, resting zone cells (RC) exhibit rapid responses to 24R,25-(OH) 2 D 3 , and the presence of a membrane receptor, distinct from that of the 1,25-mVDR, has been shown in growth plate chondrocytes and osteoblasts (5, 11).
D receptor for either metabolite or the membrane receptor for 1␣,25-(OH) 2 D 3 .
Activation of membrane receptors may lead to gene expression through a number of signaling pathways. This is a relatively new concept for lipophilic hormones such as the vitamin D metabolites [see and Boyan et al. (3) for reviews]. Membrane receptors for 1␣,25-(OH) 2 D 3 and 24R,25-(OH) 2 D 3 both mediate target cell response through activation of protein kinase C␣ (PKC␣) (18, 19) , but different mechanisms are involved. In growth zone cartilage cells (18) and skeletal muscle cells (20, 21) , PKC is stimulated by 1␣,25-(OH) 2 D 3 via activation of phosphatidylinositol-specific phospholipase C (PLC), resulting in the formation of diacylglycerol and inositol-1,4,5-trisphosphate (22) . 1␣,25-(OH) 2 D 3 also activates phospholipase A 2 (23, 24) , resulting in the release of arachidonic acid (25, 26) , which then serves as a substrate for cyclooxygenase-1 (27) . Prostaglandin (PG) production is increased (28) , and PGE 2 participates in the mechanism by acting on its EP1 receptor to produce activated G q and increase PKC activity (29) . 1␣,25-(OH) 2 D 3 has no effect on PKC in RC. 1␣,25-(OH) 2 D 3 also stimulates protein kinase A (PKA) in muscle cells (30, 31) via G protein phosphorylation. In contrast, 24R,25-(OH) 2 D 3 increases PKC via phospholipase D (PLD)-dependent production of diacylglycerol (32) . There is a rapid inhibition of phospholipase A 2 activity (25) , reducing the amount of arachidonic acid available for cyclooxygenase-1, and ultimately causing a reduction in the production of PG (28) . This has a stimulatory effect on PKC, however, because the PKA pathway is inhibitory of the 24R,25-(OH) 2 D 3 effect in these cells (33) . 24R,25-(OH) 2 D 3 has no effect on PKC in growth zone cells (GC) .
Inhibition of PKC blocks many of the physiological responses of GC to 1␣,25-(OH) 2 D 3 and of RC to 24R,25-(OH) 2 D 3 (3) , indicating that the pathways initiated by activation of the enzyme have genomic consequences. This is true for PKA-dependent signaling as well (29, 33) . Signal transduction pathways mediated by PKC and PKA converge at the activation of MAPK in many cells (15, 34, 35) . This is of particular significance because MAPK phosphorylates transcription factors, such as activating protein-1 (36) , thereby modulating gene expression. Whether this is the case for chondrocytes in response to these vitamin D metabolites is not known.
There are three major families of MAPK: the ERK family, the c-Jun N-terminal kinase (JNK)/stretch-activated MAPKs, and p38 (34) . The ERK family consists of two proteins, p42 (ERK2) and p44 (ERK1), that are activated by phosphorylation on tyrosine residues by MAPK kinase (MEK) (37) . Once activated, ERK1/2 then act as serine kinases (34) . Recent reports indicate that ERK MAPKs may mediate the effects of 1␣,25-(OH) 2 D 3 . Inhibition of ERK1/2 activity with PD98059 blocks the effects of 1␣,25-(OH) 2 D 3 on MG63 cells, including the synergistic increases in alkaline phosphatase activity observed when these cells are cultured on titanium surfaces with rough microtopographies (38) . ERK1/2 are involved in regulating aggrecan expression in bovine articular chondrocytes (39) , as is alkaline phosphatase in osteoblasts (40) . However, it is not known whether cell membrane-mediated physiological responses to 1␣,25-(OH) 2 D 3 and 24R,25-(OH) 2 D 3 are via ERK1/2 or only a subset of responses.
Recent studies suggest that increased MAPK activity in response to 1␣,25-(OH) 2 D 3 does not require new enzyme expression, but is due to increased phosphorylation of existing ERK1/2 (15, 35) . Moreover, the effect is mediated by membrane-associated mechanisms. In NB4 cells, p42 phosphorylation is increased by 6-s-cis-locked analogs of 1␣,25-(OH) 2 D 3 , but not by 6-s-trans-locked analogs (15) , indicating that the secosteroid must be in a 6-s-cis conformation. 6-scis-locked analogs activate rapid responses of NB4 cells, intestinal epithelial cells, and osteoblasts and exhibit very low affinity for the 1,25-nVDR (15, 41) (45, 46) , H-89 (PKA inhibitor) (47), U73122 (phosphatidylinositol-specific PLC inhibitor) (48) , wortmannin (PLD inhibitor) (49) , actinomycin D (transcription inhibitor), and cycloheximide (translation inhibitor). Indomethacin (cyclooxygenase inhibitor) was purchased from Sigma (St. Louis, MO). The Biotrack p42/p44 MAPK assay kit was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). DMEM was obtained from Life Technologies, Inc. (Gaithersburg, MD), and fetal bovine serum was purchased from Atlanta Biologicals (Norcross, GA). The protein content of each sample was determined using the bicinchoninic acid protein assay reagent (50) 
Chondrocyte cultures
The culture system used in this study has been described in detail previously (51) . Chondrocytes were isolated from the resting zone (reserve zone) and growth zone (prehypertrophic/upper hypertrophic cell zones) of the costochondral junction of 125-g male Sprague Dawley rats and cultured in DMEM containing 10% fetal bovine serum and 50 g/ml vitamin C in an atmosphere of 5% CO 2 (50) and MAPK activity. Fifteen microliters of each experimental sample were mixed with 10 l substrate buffer and 5 l Mg/ATP reagent, both provided in the kit. Immediately before use, [ 32 P]ATP was added to the Mg/ATP reagent to a final concentration of 200 Ci/ml. After a 30-min incubation at 30 C, the reaction was stopped by addition of 10 l stop reagent, the samples were centrifuged for 15 sec at 14,000 rpm, and 30 l were spotted onto phosphocellulose discs. The discs were washed twice with 75 mm orthophosphoric acid and once with distilled water and were counted in a liquid scintillation counter.
Western blot analysis
Chondrocytes have been shown to express ERK1/2, p38, and JNK (39, (52) (53) (54) (55) (56) (57) (58) ; however, this work focused only on the ERK1/2 family. To determine whether 1␣,25-(OH) 2 D 3 or 24R,25-(OH) 2 D 3 regulated the levels of ERK1/2 protein or MAPK was activated by tyrosine phosphorylation (34), cell culture lysates were examined by Western blot using specific antibodies to nonphosphorylated and phosphorylated p42/p44. Cell culture lysates were prepared from confluent, fourth passage growth zone cell cultures that had been treated for 1, 9, or 90 min with 10 Ϫ8 m 1␣,25-(OH) 2 D 3 , or from resting zone cell cultures treated for 1, 9, 90, or 270 min with 10 Ϫ7 m 24R,25-(OH) 2 D 3 and were resolved on 10% SDS-polyacrylamide gels. Similar gels were run using cell culture lysates prepared from GC cultures treated for 9 min with 10 Ϫ10 , 10
Ϫ9
, or 10
Ϫ8
m 1␣,25-(OH) 2 D 3 or from RC cultures treated for 90 min with 10 Ϫ9 , 10 Ϫ8 , or 10 Ϫ7 m 24R,25-(OH) 2 D 3 . Blots of the gels were probed with 1:5000 dilutions of rabbit polyclonal antibodies to phosphorylated p42/p44 or nonphosphorylated p42/p44 (Promega Corp., Madison, WI), followed by 1:5000 dilutions of alkaline phosphatase-conjugated antirabbit IgG1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The ERK1 (44 kDa) and ERK2 (42 kDa) bands were visualized using the nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate reagent (Sigma).
MAPK mRNA levels
To determine whether chondrocytes express genes for ERK1 and ERK2, RNA preparations from RC and GC cultures were screened by RT-PCR. Total RNA was isolated with TRIzol reagent (Life Technologies, Inc.). For sequence determination, total RNA from RC and GC were reverse transcribed with the First-Strand cDNA synthesis kit (Pharmacia Biotech, Piscataway, NJ) and sequenced by the Center for Advanced DNA Technologies, Department of Microbiology, University of Texas Health Science Center (San Antonio, TX). For rat brain, kidney, and liver RNA samples, 1 g total RNA (purchased from Ambion, Inc., Austin, TX) was used in reverse transcriptase reactions. Rat primer sequences were generated from rat sequences (available in GenBank) and based on primer sequences shown to amplify rat ERK cDNAs. The sets of ERK primers were: ERK1 sense, 5Ј-GAT TGC TGA CCC TGA GCA C-3Ј; and ERK1 antisense, 5Ј-GGG GGC CTC TGG TGC C-3Ј; ERK2 sense, 5Ј-GCC CGG AGA TGG TCC GC-3Ј; and ERK2 antisense, 5Ј-ATG GTC TGG ATC TGC AAC A-3Ј. The expected product sizes were 570 bp (ERK1) and 506 bp (ERK2). Rat brain RNA served as positive control template for ERK1 and ERK2. Sequences were confirmed by direct comparison with published rat ERK1 and ERK2 sequences available in GenBank [ERK1, accession no. M61177 (59); ERK2, accession no. M64300 (60)].
Northern blot analysis
To quantitate the effects of 1␣,25-(OH) 2 D 3 on mRNA levels for ERK1 and ERK2, we performed Northern blot analysis. Total RNA for untreated and 1␣,25-(OH) 2 D 3 -treated growth zone chondrocytes as well as from untreated and 24R,25-(OH) 2 D 3 -treated RC was isolated with TRIzol. Total RNA was quantitated spectrophotometrically, separated on a 1% denaturing agarose gel, and transferred to a positively charged nylon membrane (Ambion, Inc.) with the Turboblotter System (Schleicher & Schuell, Inc., Keene, NH). Northern blots were hybridized with ERK1, ERK2, and glyceraldehyde-3-phosphate dehydrogenase-strippable 32 P-labeled anticoding RNA probes using the NorthernMax Kit (Ambion, Inc.). ERK1 and ERK2 DNA templates were synthesized from sequenced RT-PCR products amplified with modified antisense primers with the T7 promoter sequence, 5Ј-TAA TAG GAC TCA CTA TAG GGA GG-3Ј, attached to the 5Ј-end of the antisense primers. Anticoding RNA probes were synthesized with the Strip-EZ T7 Kit (Ambion, Inc.). Northern blots were analyzed with a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA). 
Requirement for gene expression and protein synthesis
To determine whether new gene expression or protein synthesis is required for 1␣,25-(OH) 2 D 3 -and 24R,25-(OH) 2 D 3 -dependent stimulation of MAPK activity, growth zone and resting zone chondrocytes were treated with 1, 10, or 100 m actinomycin D to block transcription or with 1, 10, or 100 m cycloheximide to block translation (61) . These doses were selected based on previous studies using the costochondral growth plate chondrocyte model (18, 61) .
PKC and PKA
1␣,25-(OH) 2 D 3 mediates its effects on GC via the PKC and PKA signaling pathways (62) . These pathways also mediate the effects of 24R,25-(OH) 2 D 3 on RC (4). To determine whether activation of MAPK involved one or both mechanisms, specific inhibitors of each pathway were used. Two different inhibitors were used to inhibit PKC, chelerythrine (0.1, 1, or 10 m) (45) and H-7 (0.1 or 1 m) (46) . Growth zone chondrocyte cultures were incubated for 9 min in control medium or medium containing 10 Ϫ8 m 1␣,25-(OH) 2 D 3 with or without chelerythrine or H-7, resting zone cultures were incubated for 90 min in control medium or medium containing 10 Ϫ7 m 24R,25-(OH) 2 D 3 with or without chelerythrine or H-7, and MAPK activity was determined. The involvement of PKA was assessed in a similar manner using the PKA inhibitor H-89 (0.1 or 1 m) (47).
PLC
PLC mediates the effects of 1␣,25-(OH) 2 D 3 on PKC in growth zone cell cultures (22) , but does not mediate the effects of 24R,25-(OH) 2 D 3 on RC (63) . Its involvement in the effect of vitamin D 3 metabolites on MAPK was assessed by using U73122, an inhibitor of phosphatidylinositol specific (PI)-PLC (48), at 0.1, 1.0, or 10 m. Growth zone chondrocytes were incubated for 9 min in control medium or medium containing 10 
Cyclooxygenases
Inhibition of PG synthesis blocks the effects of 1␣,25-(OH) 2 D 3 on PKC in GC and augments the effects of 24R,25-(OH) 2 D 3 in RC (27, 65) . Involvement of PGs in the regulation of MAPK by these metabolites was assessed using indomethacin, a general inhibitor of cyclooxygenases. GC were incubated for 9 min in control medium or medium containing 10 
Statistical management of data
For each experiment, each value represents the mean Ϯ sem of the cell layers of six individual independent cultures. Significance between groups was determined by ANOVA. Bonferroni's modification of the t test was used for post hoc testing. P Ͻ 0.05 was considered significant. Each experiment was repeated two or more times to ensure the validity of the data. The data presented are from a single representative experiment. ysis (Fig. 1) , and the amount of expression was similar in both types of cells.
Results

GC
There was a time-dependent decrease in MAPK activity in controls of the RC cultures (Fig. 2) . This was due to the experimental design. The addition of fresh medium to these cultures at time zero increased enzyme activity. As bioactive agents in the medium were depleted, the medium-dependent stimulation was reduced. This effect was not seen in the GC cultures. 1␣,25-(OH) 2 D 3 regulated MAPK specific activity of GC in a time-dependent manner ( Fig. 2A) . Enzyme activity was increased by 10 Ϫ8 m within 9 min, and the greatest activity was observed at 90 min. By 180 min, MAPK activity had returned to control levels. The effect of 1␣,25-(OH) 2 D 3 was dose dependent (Fig. 2B) . Increased activity was noted in cultures treated with 10 Ϫ10 m, and the highest levels of activity were seen in cultures treated with 10 Ϫ8 m 1␣,25-(OH) 2 D 3 . RC responded to 24R,25-(OH) 2 D 3 in a timedependent manner as well, but the effect on MAPK did not occur until after 9 min (Fig. 2C) . Peak activity was seen at 90 min and remained elevated over control cultures through 270 min. The effect of 24R,25-(OH) 2 D 3 was dose dependent, with greatest activation at 10 Ϫ7 m (Fig. 2D ). These observations were consistent, as indicated by analysis of treatment/control ratios of five independent experiments (data not shown).
The effects of 1␣,25-(OH) 2 D 3 and 24R,25-(OH) 2 D 3 on MAPK were stereospecific and cell maturation specific (data not shown). 1␣,25-(OH) 2 D 3 had no effect on MAPK activity in RC, and 24R,25-(OH) 2 D 3 had no effect on MAPK in GC. Only 1␣,25-(OH) 2 D 3 stimulated enzyme activity in GC; 1␤,25-(OH) 2 D 3 was without effect. Similarly, only 24R,25-(OH) 2 D 3 stimulated enzyme activity in RC; 24S,25-(OH) 2 D 3 was without effect.
The effect of the vitamin D metabolites on MAPK activity was not due to a change in gene expression in either cell type (Fig. 1) . No change in p44 or p42 mRNA levels were noted in Northern blots of RNA isolated from GC treated with 1␣,25-(OH) 2 D 3 at any of the time points (9 and 90 min and 24 h) examined. Similarly, 24R,25-(OH) 2 D 3 did not affect mRNA levels in RC.
Protein synthesis was also not responsible for the change Moreover, there were no changes in p42 or p44 protein levels in Western blots of the cell lysates (data not shown). In contrast, phosphorylation of ERK1/2 was regulated by the vitamin D metabolites in a time-and dose-dependent manner (Fig. 3) . Phosphorylated p42 and p44 were evident in GC treated with 10 Ϫ8 m 1␣,25-(OH) 2 D 3 as early as 1 min, and the greatest phosphorylation was achieved at 90 min. Phosphorylation was seen in cultures treated with 10 Ϫ10 m, particularly the p42 band. The greatest amount of phosphorylation was seen in cultures treated with 10 Ϫ8 m 1␣,25-(OH) 2 D 3 . The effect of 24R,25-(OH) 2 D 3 on the phosphorylation of MAPK in RC was similar. Phosphorylated p42/p44 was evident within 1 min and increased over time, becoming maximal at 90 min. By 270 min, there was no more evidence of phosphorylated enzyme. Phosphorylation was dose dependent, with the greatest amount in cells cultured in the presence of 10 Ϫ7 m 24R,25-(OH) 2 D 3 .
In both GC and RC, MAPK activity was regulated by a PKC-dependent mechanism that did not involve PKA. Inhibition of PKC with chelerythrine caused a dose-dependent decrease in 1␣,25-(OH) 2 D 3 -stimulated MAPK in GC (Fig. 4A) and 24R,25-(OH) 2 D 3 -stimulated MAPK in RC (Fig. 4B) . Chelerythrine did not alter MAPK activity in control cultures. Similar effects were found when the cultures were treated with the PKC inhibitor H-7 (data not shown). However, when the cells were treated with the PKA inhibitor H-89, there was no change in MAPK activity in the control cultures or in cultures treated with 1␣,25-(OH) 2 D 3 (Fig. 4C) (Fig. 4D) .
The effect of 1␣,25-(OH) 2 D 3 on MAPK involved PI-PLC, but not PLD. The PI-PLC inhibitor U73122 caused a dosedependent decrease in the MAPK activity of the treated GC cultures (Fig. 5A ), but the PLD inhibitor wortmannin was without effect (Fig. 5B) . In contrast, U73122 had no effect on MAPK in RC treated with 24R,25-(OH) 2 D 3 (Fig. 5C) , whereas activity was inhibited by wortmannin (Fig. 5D) .
Inhibition of cyclooxygenase activity by indomethacin affected MAPK activity in GC and RC in different ways (Table  1) . Indomethacin reduced MAPK activity in control cultures of GC and partially reduced the increase in enzyme activity due to 1␣,25-(OH) 2 D 3 . In contrast, indomethacin stimulated MAPK activity in control cultures of RC to the same extent (Fig. 6, A and  D) . In GC, the effects of 1 and 10 m PD98059 were similar to the effect of 10 Ϫ8 m 1␣,25-(OH) 2 Proteoglycan sulfation was mediated in part by ERK1/2 in GC (Fig. 6B ). PD98059 caused a dose-dependent decrease in control cultures that was significant only at the two highest concentrations, and a similar decrease was noted in the 1␣,25-(OH) 2 D 3 -treated cultures. In contrast, ERK1/2 mediated the effect of 24R,25-(OH) 2 D 3 on [
35 S]sulfate incorporation by RC cultures (Fig. 6E) . The inhibitor caused a small decrease in proteoglycan sulfation in control cultures at the highest concentration used, and it blocked the 24R,25-(OH) 2 D 3 -stimulated increase in a dose-dependent manner. Alkaline phosphatase specific activity was not regulated via ERK1/2 in either control cultures or cultures treated with the appropriate vitamin D 3 metabolite (Fig. 6, C and F) .
Discussion
The results of this study demonstrate for the first time that the ERK1/2 MAPKs are regulated by 1␣,25-(OH) 2 The effects of the vitamin D metabolites are due to activation via phosphorylation and not via a change in mRNA levels or protein synthesis. These results support those of Morelli et al. (35) showing that 1␣,25-(OH) 2 D 3 stimulates the phosphorylation of p42 and p44 in skeletal muscle cells. In addition, our results support the observations of Song et al. (15) , indicating that p42 is phosphorylated to a greater extent than p44 in response to 1␣,25-(OH) 2 D 3 . Further, our results show that 24R,25-(OH) 2 D 3 increases phosphorylation of both ERKs to a similar extent, suggesting that p44 phosphorylation may involve a mechanism specific to the action of this metabolite.
The cell specificity of the responses to 1␣,25-(OH) 2 D 3 and 24R,25-(OH) 2 D 3 was not due to a difference in the amount of ERK1/2 present in control cultures. No differences were noted in the levels of mRNA or protein. However, activity in the control cultures differed, with RC having approximately 3 times more specific activity than GC. This supports the observation of Oh et al. (58) that as chondrocyte differentiation increases in chick limb buds, MAPK activity decreases.
Stereospecificity argues for a receptor-mediated mechanism. It is likely that the change in MAPK activity is due to activation of membrane receptors rather than to the 1,25-nVDR for a number of reasons. First and foremost is the lack of evidence for a change in gene expression or protein synthesis, as noted above. Secondly, a nuclear receptor for 24R,25-(OH) 2 D 3 has not yet been isolated, yet 24R,25-(OH) 2 D 3 modulated MAPK activity and ERK1/2 phosphorylation in RC. Finally, MAPK activity in both cell types was regulated via a PKC-dependent mechanism as well as by signaling pathways previously shown to regulate PKC activity in response to the vitamin D metabolites in a cellspecific manner. 1␣,25-(OH) 2 D 3 has been repeatedly shown to stimulate PKC␣ activity only in GC, whereas 24R,25-(OH) 2 D 3 increases PKC␣ activity only in RC (18) . Moreover, 1␣,25-(OH) 2 D 3 increases PKC via a PLC-dependent mechanism only in GC (22) , whereas 24R,25-(OH) 2 D 3 increases PKC via a PLD-dependent mechanism only in RC (63) .
The involvement of PKC in the activation of MAPK was demonstrated clearly using two separate inhibitors, chelerythrine and H-7. PKC also mediates the effects of 1␣,25-(OH) 2 D 3 on MAPK in smooth muscle cells (35) . Chelerythrine is commonly used to block PKC-dependent effects, but it has been reported to inhibit PKA at high concentrations (73) , much higher than those used in the present study. It is unlikely that PKA plays a role in the activation of MAPK by either 1␣,25-(OH) 2 D 3 or 24R,25-(OH) 2 D 3 , however, because H-89 had no effect on either enzyme activity in control cultures or in cultures treated with the vitamin D metabolites. In contrast, PKA is involved in the regulation of MAPK in response to other regulatory factors (40, 55, 57) . PGs appear to be involved in the maintenance of MAPK at basal levels in growth plate chondrocytes, as indomethacin caused a decrease in activity in control cultures of GC and an increase in activity in RC. Whether this is due to a change in ERK1/2 or another MAPK is not known. Similar effects have been observed when measuring PKC activity in growth plate chondrocytes in the presence of indomethacin (22, 32 E) . The effect on cell differentiation was assessed by measuring alkaline phosphatase specific activity (C and F). Values are the mean Ϯ SEM for six cultures from one experiment. The experiment was repeated with nearly identical results. *, P Ͻ 0.05 vs. not treated with MAPK inhibitor; #, P Ͻ 0.05 vs. control for a particular vitamin D 3 metabolite treatment.
suggesting that one role of the differential response of phospholipase A 2 to the vitamin D metabolites is to optimize PG levels for signal transduction via PKC and MAPK.
The effect of 1␣,25-(OH) 2 D 3 on MAPK was partially blocked by indomethacin, but it is possible that this reflects the reduction in basal activity. 1␣,25-(OH) 2 D 3 stimulates PKC via a mechanism that involves PG production; inhibition of cyclooxygenase-1 reduces the effect of 1␣,25-(OH) 2 D 3 on PKC via PGE 2 -dependent activation of the E-series prostanoid-1 receptor (27, 29) . As 1␣,25-(OH) 2 D 3 increases MAPK via a PKC-mediated pathway, the partial reduction in enzyme activity may reflect the decrease in PKC due to indomethacin. In RC, the effect of indomethacin was comparable to that of 24R,25-(OH) 2 D 3 alone, and it augmented the effect of this vitamin D metabolite, suggesting that PGs are involved in the mechanism in these cells as well. PKC activity is stimulated by inhibition of PG synthesis, in part because of the reduction of PKA-dependent inhibition of this signaling pathway (74) .
This study supports the observation that 1␣,25-(OH) 2 3 H]thymidine incorporation and increases alkaline phosphatase specific activity in RC via a 24,25-mVDR and PKC (5), but, again, ERK1/2 is not involved. In contrast to our results, MAPK does mediate the effects of T 3 on alkaline phosphatase in osteoblasts (40) . It is unlikely that the decrease in proliferation or the increase in activity of this enzyme in response to 1␣,25-(OH) 2 D 3 or 24R,25-(OH) 2 D 3 are due only to a nongenomic mechanism, although nongenomic regulation does play a role, at least with respect to matrix vesicle enzyme activity (76) . It is more likely that other MAPKs, such as JNK and p38, or other PKC-dependent signaling mechanisms are involved in the response of growth plate chondrocytes.
It is also evident that there are differences between the two maturation states in the management of the response to either metabolite via MAPK. This signaling pathway plays little, if any, role in the use of sulfate by GC in response to 1␣,25-(OH) 2 D 3 , although ERK MAPKs do mediate the effects of TGF␤ on aggrecan expression in ATDC5 cells (39) . In contrast, proteoglycan synthesis by RC in response to 24R,25-(OH) 2 D 3 is sensitive to ERK1/2 inhibition, supporting the hypothesis that the 24,25-mVDR must rely on nonnuclear vitamin D receptor-mediated mechanisms. This appears to be the case for the antiproliferative response as well.
In summary, this paper supports the hypothesis that 1␣,25-(OH) 2 D 3 regulates the physiology of growth zone chondrocytes via rapid membrane-mediated signaling pathways. Some, but not all, of the response to 1␣,25-(OH) 2 D 3 is via the ERK family of MAPKs, involving rapid PKC-dependent phosphorylation of p42 and, to a lesser extent, p44. This paper also shows for the first time that 24R,25-(OH) 2 D 3 exerts its cell-specific effects on resting zone chondrocytes via PKCdependent MAPK, affecting phosphorylation of p42 and p44 to a comparable extent. Whereas 1␣,25-(OH) 2 D 3 increases MAPK activity via PLC and increased PG production, 24R,25-(OH) 2 D 3 increases MAPK via PLD and decreased PG production. PKA is not involved in the activation of ERK1/2 in either cell type. The stereospecificity of the effects of each metabolite, the cell specificity of the effect, and the dependence on PKC argue for the participation of membrane receptors for 1␣,25-(OH) 2 D 3 and 24R,25-(OH) 2 D 3 in the regulation of ERK1/2 in the growth plate.
